Description
Tirzepatide, identified during development as LY3298176, is a peptide with agonist activity at glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its scientific background includes discovery research and experiments comparing receptor responses. This 20mg listing provides the correctly spelled compound name and a distinct catalogue quantity.
Mechanism & Research Background
The dual-receptor profile makes tirzepatide different from a GLP-1-only analogue and from a triple agonist that also targets the glucagon receptor. Published pharmacology has examined how tirzepatide engages GIP and GLP-1 receptors, including differences in signalling behaviour at each target. The relative response depends on the receptor system and assay conditions rather than on the name alone.
Areas of Research
- GIP and GLP-1 receptor activation and comparative pharmacology.
- Differences between receptor binding and downstream signalling measurements.
- Dual- versus single-receptor activity in defined research models.
The 20mg entry provides a larger listed quantity than the separate 10mg product, without implying a different mechanism or greater efficacy. Quantitative experiments depend on documented material content and preparation conditions. Findings from pharmaceutical studies should not be treated as proof that a supplier’s research batch matches a finished medicine.
Product Details
- Product: Tirzepatide 20mg
- Listed quantity: 20mg
- Compound class: Dual GIP and GLP-1 receptor agonist peptide
- Product code: TR20
Storage & Handling
Follow the storage conditions and handling guidance in the applicable supplier documentation. Protect the material from unsuitable heat, light and moisture, and record the batch used in each experiment. Preparation and storage requirements depend on the supplied formulation and the research method.
Batch Documentation
Certificates of analysis should be matched to the product and batch. Consult the relevant report for measured identity, content and purity; a purity result alone does not establish sterility or endotoxin status.
Research References
Important Notice
Premium research peptides synthesised and shipped from Australia. For in-vitro research purposes only. Strictly not for human or veterinary consumption. All products supplied are strictly for laboratory research and development. This information describes the compound’s research background and does not provide dosing instructions or claim a therapeutic benefit.
Reviews
There are no reviews yet.